N2 year in review and message from the editor to our reviewers
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published December 19, 2018.
Author Disclosures
- Josep Dalmau, MD, PhD,
- Dennis L. Kolson, MD, PhD,
- Friedemann Paul, MD and
- Scott S. Zamvil, MD, PhD
- Josep Dalmau, MD, PhD,
NONE
NONE
NONE
Neurology, Neuroimmunology and Neuroinflammation Neurology UpToDate
Patent for Ma2 autoantibody test: US 6,387,639; Issued May 14th, 2002. Patent for NMDA receptor autoantibody test: US 7,972,796 B2 July 5, 2011; European 2057466. Patent for GABAb receptor autoantibody test: US 8,685,656; European 2483417; Patents filed for GABA(A) receptor autoantibody test, DPPX autoantibody test, and IgLON5 autoantibody test.
NONE
NONE
Advance Medical
NONE
NONE
NONE
NONE
-NIH, RO1NS077851, PI, 2011-2018 -Instituto Carlos III/FEDER (FIS, 14/00203 and CIBERER CB15/00010, and Proyectos Integrados de Excelencia, PIE 16/00014). -Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), and CERCA Programme Generalitat de Catalunya -Fundacio CELLEX
NONE
NONE
NONE
NMDA receptor autoantibody test/Euroimmun GABA(B)R autoantibody test/Euroimmun GABA(A)R autoantibody test/Euroimmun DPPX autoantibody test/Euroimmun Iglon5 autoantibody test/Euroimmun
Patent Ma2 autoantibody test Patent NMDAR autoantibody test Patent GABA(B) receptor autoantibody test Patent application for the use of GABA(A) receptor, DPPX and IgLON5 autoantiboddy tests
NONE
NONE
NONE
- Dennis L. Kolson, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1R01 MH104134-01 (Kolson) 5/1/2014 ? 4/30/19 NIH/NIMH Oxidative stress, immune activation and therapeutic targeting in HAND The goals are to determine the association between brain regional heme oxygenase deficiency and neurocognitive impairment in HIV infected individuals, and to determine whether the simian immunodeficiency virus (SIV) primate model for neuroAIDS can be used to assess heme oxygenase- targeted therapies. Role: (PI) Overlap: There is no scientific or budgetary overlap 1R01 MH111389-01 (Kolson) 8/18/16 ? 5/31/21 NIH/NIMH Regulation of heme oxygenase in HIV/HAND pathogenesis The goals are to define the potential neuropathogenic role for a common heme oxygenase-1 promoter dinucleotide (GT)n repeat in the dysregulation of heme oxygenase-1 expression in HIV-infected individuals and determine the associated mechanisms of blood-brain barrier dysfunction. Role: (PI) Overlap: There is no scientific or budgetary overlap 1R01NS101156-01A1: (Talos) 1/01/2018-12/31/2023 NIH/NINDS The role of oxidative stress and inflammation in epileptogenesis The goals are to investigate specific blood and brain tissue biomarkers of inflammation and oxidative stress in mouse models of epileptogenesis, and to test novel neuroprotective strategies to prevent the development of chronic epilepsy and/or its neuropsychiatric co-morbidities. Role: Co-I Overlap: There is no scientific or budgetary overlap 1P30MH097488-01A1: (Evans) 6/03/13 - 05/31/18 NIH/NIMH Penn mental health AIDS research center This Center will specifically focus on the combination of mental illness and HIV/AIDS and related comorbidities to develop innovative, integrated treatments to optimize psychiatric, behavioral, and medical outcomes and to achieve a better understanding of the biological, psychological, and behavioral mechanisms underlying these combined illnesses and treatments. Dr. Kolson serves as consultant and scientific advisor for studies of HIV- associated neurocogntive disorders (HAND) and their relationship to psychiatric illnesses. Role: Co-I Overlap: There is no scientific or budgetary overlap
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Friedemann Paul, MD and
Novartis OCTIMS study steering committee MedImmune steering committee
NONE
speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire
Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation
NONE
NONE
NONE
consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion
NONE
NONE
NONE
Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono
German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)
NONE
Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA
NONE
NONE
NONE
NONE
NONE
NONE
- Scott S. Zamvil, MD, PhD
Dr. Zamvil has received honoraria for serving on Data Safety Monitoring Boards for MS trials conducted by Opexa, BioMS, Teva Pharmaceuticals, Inc. and Eli Lilly and Co. He is a member of the Clinical Advisory Board for the Myelin Repair Foundation.
NONE
NONE
(1) Neurology, Neuroimmunology and Neuroinflammation, Deputy Editor, 2014-present
NONE
NONE
NONE
SSZ has served as a consultant to Biogen Idec, Teva Neuroscience, EMD-Serono, Genzyme, Novartis and Roche.
Advanced Health Media, 2009-present Biogen, 2009-present
NONE
NONE
(1) Biogen (2) Teva
NIH RO1 NS092835-01
NMSS RG 1701-26628 NMSS RG 1801-29861
Alexander M. and June L. Maisin Foundation, PI
NONE
NONE
NONE
NONE
NONE
NONE
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Article
Neurologic autoimmunity and immune checkpoint inhibitorsAutoantibody profiles and outcomesElia Sechi, Svetomir N. Markovic, Andrew McKeon et al.Neurology, August 13, 2020 -
Views & Reviews
Neurologic Adverse Events of Immune Checkpoint InhibitorsA Systematic ReviewAlessandro Marini, Andrea Bernardini, Gian Luigi Gigli et al.Neurology, March 02, 2021 -
Article
Updated Diagnostic Criteria for Paraneoplastic Neurologic SyndromesFrancesc Graus, Alberto Vogrig, Sergio Muñiz-Castrillo et al.Neurology: Neuroimmunology & Neuroinflammation, May 18, 2021 -
Editor's Corner
N2 year in reviewJosep Dalmau, Marinos C. Dalakas, Dennis L. Kolson et al.Neurology: Neuroimmunology & Neuroinflammation, December 12, 2019